PTSD

7
Pipeline Programs
6
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
7 programs
3
4
TNX-102 SLPhase 31 trial
TNX-102 SLPhase 31 trial
TNX-102 SLPhase 31 trial
TNX-102 SL 5.6 mgPhase 31 trial
TNX-102 SLPhase 21 trial
+2 more programs
Active Trials
NCT05372887Withdrawn0Est. Nov 2022
NCT02277704Completed245Est. May 2016
NCT02421679Completed159Est. May 2016
+4 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Big MindN/A1 trial
Active Trials
NCT02541630WithdrawnEst. Apr 2016
Carrick Therapeutics
Carrick TherapeuticsIreland - Dublin
1 program
Functional Neurological RehabilitationN/A1 trial
Active Trials
NCT02003352CompletedEst. Sep 2014
Providence Therapeutics
1 program
NEST-1N/A1 trial
Active Trials
NCT02981381CompletedEst. Oct 2018
Alliance Pharmaceuticals
1 program
PARTS-SUDN/A1 trial
Active Trials
NCT06207409Completed19Est. Mar 2025
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Traditional Exposure TherapyN/A1 trial
Active Trials
NCT06740487Recruiting40Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL 5.6 mg
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Johnson & JohnsonTraditional Exposure Therapy
Alliance PharmaceuticalsPARTS-SUD
Providence TherapeuticsNEST-1
City TherapeuticsBig Mind
Carrick TherapeuticsFunctional Neurological Rehabilitation

Clinical Trials (12)

Total enrollment: 1,296 patients across 12 trials

NCT03841773Tonix PharmaceuticalsTNX-102 SL

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Start: Mar 2019Est. completion: Apr 2020192 patients
Phase 3Terminated
NCT03508700Tonix PharmaceuticalsTNX-102 SL 5.6 mg

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Start: Apr 2018Est. completion: Sep 201993 patients
Phase 3Completed
NCT03110575Tonix PharmaceuticalsTNX-102 SL

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Start: Jun 2017Est. completion: Jul 2018190 patients
Phase 3Terminated
NCT03062540Tonix PharmaceuticalsTNX-102 SL

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

Start: Mar 2017Est. completion: Jul 2018358 patients
Phase 3Terminated
NCT05372887Tonix PharmaceuticalsTNX-102 SL

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

Start: Oct 2022Est. completion: Nov 20220
Phase 2Withdrawn
NCT02421679Tonix PharmaceuticalsTNX-102 SL

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Start: Apr 2015Est. completion: May 2016159 patients
Phase 2Completed
NCT02277704Tonix PharmaceuticalsTNX-102 SL

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Start: Oct 2014Est. completion: May 2016245 patients
Phase 2Completed
NCT06740487Johnson & JohnsonTraditional Exposure Therapy

Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder

Start: Sep 2025Est. completion: Dec 202740 patients
N/ARecruiting
NCT06207409Alliance PharmaceuticalsPARTS-SUD

Program for Alleviating and Reducing Trauma, Stress, and Substance Use

Start: Sep 2023Est. completion: Mar 202519 patients
N/ACompleted
NCT02981381Providence TherapeuticsNEST-1

Synchronized Transcranial Magnetic Stimulation for PTSD

Start: Oct 2016Est. completion: Oct 2018
N/ACompleted
NCT02541630City TherapeuticsBig Mind

Big Mind for Veterans With PTSD

Start: Aug 2015Est. completion: Apr 2016
N/AWithdrawn
NCT02003352Carrick TherapeuticsFunctional Neurological Rehabilitation

Study of PTSD in Military Veterans Who Have Suffered Traumatic Brain Injuries

Start: Mar 2014Est. completion: Sep 2014
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,296 patients
6 companies competing in this space